Literature DB >> 3006466

Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists.

G Muiesan, E Agabiti-Rosei, G Romanelli, M L Muiesan, M Castellano, M Beschi.   

Abstract

The effects of 2 calcium antagonist drugs, verapamil and nifedipine, on blood pressure, heart rate (HR), plasma catecholamines, plasma renin activity and some echocardiographic indexes of left ventricular anatomy and function were studied in 67 patients with essential hypertension. The short- and long-term antihypertensive effect of verapamil was not associated with significant changes in HR, plasma catecholamines or plasma renin activity; the decrease in blood pressure after nifedipine was associated with a significant increase in HR and plasma catecholamines (mainly noradrenaline) (p less than or equal to 0.05). These findings were confirmed in a crossover comparison in 12 hospitalized patients treated with verapamil and nifedipine for 8 days each. The dose of isoproterenol that increased HR by 25 beats/min was significantly increased during verapamil treatment (p less than 0.05) and decreased during nifedipine treatment (p less than 0.01). Stroke volume and shortening fraction increased slightly but significantly (p less than 0.05) with 3 months of nifedipine treatment, while no change was detected with verapamil treatment. Left ventricular mass was significantly decreased after effective antihypertensive treatment for 3 months with verapamil or nifedipine (p less than or equal to 0.05).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3006466     DOI: 10.1016/0002-9149(86)90805-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Hypertension.

Authors:  G W Ching; D G Beevers
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

2.  Dose-dependent effects of verapamil and nifedipine on in vivo platelet function in normal volunteers.

Authors:  K Winther; C M Jespersen; B Rydberg; G Thamsborg; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?

Authors:  M C Ruddy
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 4.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

5.  Left ventricular mass changes with nicardipine therapy in essential hypertension.

Authors:  P Gosse; P Lacroix; R Roudaut; M Dallocchio
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

6.  Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors.

Authors:  G Ranieri; V Filitti; A Andriani; M V Bonfantino; G Lamontanara; A Cavallo; M Milani; R De Cesaris
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

Review 7.  Does a reduction in left ventricular hypertrophy reduce cardiovascular morbidity and mortality?

Authors:  F H Messerli; F Soria
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 8.  Choosing the correct drug for the individual hypertensive patient.

Authors:  L H Opie
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 10.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.